This company has been marked as potentially delisted and may not be actively trading. OvaScience (OVAS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OVAS vs. ZYME, CALT, SBTX, ETHZ, AVTE, NLTX, BIOA, VIRI, WHWK, and SPRBShould you be buying OvaScience stock or one of its competitors? The main competitors of OvaScience include Zymeworks (ZYME), Calliditas Therapeutics AB (publ) (CALT), Silverback Therapeutics (SBTX), Flag Ship Acquisition (ETHZ), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), and Spruce Biosciences (SPRB). OvaScience vs. Its Competitors Zymeworks Calliditas Therapeutics AB (publ) Silverback Therapeutics Flag Ship Acquisition Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Virios Therapeutics Whitehawk Therapeutics Spruce Biosciences OvaScience (NASDAQ:OVAS) and Zymeworks (NASDAQ:ZYME) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership. Do insiders & institutionals hold more shares of OVAS or ZYME? 22.5% of OvaScience shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 7.4% of OvaScience shares are held by insiders. Comparatively, 1.9% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to OVAS or ZYME? In the previous week, Zymeworks had 13 more articles in the media than OvaScience. MarketBeat recorded 13 mentions for Zymeworks and 0 mentions for OvaScience. Zymeworks' average media sentiment score of 0.52 beat OvaScience's score of 0.00 indicating that Zymeworks is being referred to more favorably in the news media. Company Overall Sentiment OvaScience Neutral Zymeworks Positive Which has higher earnings and valuation, OVAS or ZYME? OvaScience has higher earnings, but lower revenue than Zymeworks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOvaScience$290K1,268.88-$50.97MN/AN/AZymeworks$76.30M17.84-$122.69M-$0.97-18.67 Do analysts prefer OVAS or ZYME? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OvaScience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Zymeworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Is OVAS or ZYME more profitable? Zymeworks has a net margin of -59.96% compared to OvaScience's net margin of -10,128.37%. Zymeworks' return on equity of -21.59% beat OvaScience's return on equity.Company Net Margins Return on Equity Return on Assets OvaScience-10,128.37% -47.06% -42.39% Zymeworks -59.96%-21.59%-16.52% Which has more risk and volatility, OVAS or ZYME? OvaScience has a beta of 3.11, indicating that its stock price is 211% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. SummaryZymeworks beats OvaScience on 9 of the 13 factors compared between the two stocks. Get OvaScience News Delivered to You Automatically Sign up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OVAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OVAS vs. The Competition Export to ExcelMetricOvaSciencePharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$367.97M$787.62M$6.05B$10.30BDividend YieldN/A4.84%5.73%4.82%P/E RatioN/A1.2885.3127.10Price / Sales1,268.8829.85601.46133.29Price / CashN/A17.6425.7730.18Price / Book5.717.5412.676.69Net Income-$50.97M-$7.59M$3.32B$276.55M OvaScience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OVASOvaScienceN/A$10.27-4.7%N/A+902.0%$367.97M$290K0.00N/AZYMEZymeworks0.0668 of 5 stars$16.92+1.4%N/AN/A$1.27B$76.30M-17.44460News CoverageAnalyst UpgradeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180SBTXSilverback TherapeuticsN/A$11.11+7.6%N/A-22.0%$400.60MN/A-4.5983High Trading VolumeETHZFlag Ship AcquisitionN/A$2.19-5.6%N/AN/A$360.10MN/A-0.157Gap UpAVTEAerovate TherapeuticsN/A$9.08+0.4%N/A-87.8%$263.18MN/A-3.0420High Trading VolumeNLTXNeoleukin TherapeuticsN/A$23.47+1.6%N/A-38.9%$220.57MN/A-7.5590High Trading VolumeBIOABioAge Labs0.182 of 5 stars$5.45-3.9%N/AN/A$195.38MN/A0.00N/AVIRIVirios TherapeuticsN/A$6.38-5.6%N/A+30.3%$122.87MN/A-23.635Gap DownWHWKWhitehawk Therapeutics0.9943 of 5 stars$2.17+1.9%N/AN/A$102.27M$21.60M-36.1721SPRBSpruce Biosciences0.6543 of 5 stars$175.31+9.5%$131.25-25.1%+421.0%$98.17M$4.91M-2.0320Gap UpHigh Trading Volume Related Companies and Tools Related Companies ZYME Competitors CALT Competitors SBTX Competitors ETHZ Competitors AVTE Competitors NLTX Competitors BIOA Competitors VIRI Competitors WHWK Competitors SPRB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OVAS) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OvaScience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OvaScience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
